生命科学资讯

BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline

United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris - BioSpace

Roche gets third pivotal win with MS drug, but liver signal could be a problem

FDA lifts hold on second Intellia Phase 3 gene editing trial

Stifel raises 10X Genomics stock price target on product adoption - Investing.com

Med-tech outlook 2026: exits, financings, headwinds

Biggest gainers and losers for Feb. 23-27, 2026

Candid to go public via reverse merger with Rallybio

10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat

Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover

Atrium Tx launches with Avidity's RNA ticker and cardio assets

Safety concerns spur Aardvark to halt key Prader-Willi drug trial

Big Pharma’s next entrant could come from China

Shionogi synthesizes new compounds for malaria

UniQure says FDA prefers randomized trial for Huntington's treatment

Agilent Technologies, Inc. (A) Stock Analysis: Exploring a 34.15% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews

Thermo Fisher Scientific Inc. $TMO Stock Holdings Increased by Fisher Asset Management LLC - MarketBeat